Napredna pretraga

Pregled bibliografske jedinice broj: 60915

Lansoprazole versus omeprazole in the treatment of reflux esophagitis.


Včev, Aleksandar; Štimac, Davor; Včeva, Andrijana; Rubinić, Milivoj; Ivandić, Ante; Ivaniš, Nikola; Horvat, Darko; Volarić, Miroslav; Karner, Ivan;
Lansoprazole versus omeprazole in the treatment of reflux esophagitis. // Acta Medica Croatica. 51(3):171-4, 1997., 51 (1997), 3; 171-174 (međunarodna recenzija, članak, znanstveni)


Naslov
Lansoprazole versus omeprazole in the treatment of reflux esophagitis.

Autori
Včev, Aleksandar ; Štimac, Davor ; Včeva, Andrijana ; Rubinić, Milivoj ; Ivandić, Ante ; Ivaniš, Nikola ; Horvat, Darko ; Volarić, Miroslav ; Karner, Ivan ;

Izvornik
Acta Medica Croatica. 51(3):171-4, 1997. (1330-0164) 51 (1997), 3; 171-174

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Reflux esophagitis; lansoprazole;omeprazole

Sažetak
Abstract To evaluate the therapeutic potential of the newly developed proton pump inhibitor lansoprazole in patients with reflux esophagitis (grade I and II according to Savary Muller criteria), the authors performed a single blind, randomized clinical trial comparing 20 mg omeprazole and 30 mg lansoprazole, involving 60 patients at two clinical hospitals. The treatment period was or 8 weeks, and main efficacy variables were healing of endoscopic changes and relief of reflux symptoms. No significant difference in terms of healing and relief of reflux symptoms was found either after 4 or after 8 weeks of treatment. In conclusion, 30 mg lansoprazole daily was found to be safe and effective therapy comparable to omeprazole in the short-term treatment for reflux esophagitis (grade I and II).

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita

Časopis indeksira:


  • Scopus
  • MEDLINE